… We reviewed emerging immune strategies for multiple myeloma (MM) therapy excluding
US FDA approved drugs. In relapsed refractory MM, isatuximab (anti-CD38) monotherapy …

… new therapeutic approaches. In this review we discuss the current treatment paradigm of
multiple myeloma … therapeutic potential of emerging preclinical research in multiple myeloma. …

… tremendous progress in terms of new therapies for multiple myeloma (MM), paralleled by a
… effort to identify new therapeutic targets in MM. Broadly, the therapeutic targets in MM can be …

… It has been associated with resistance to new … new therapeutic strategies to overcome
resistance to current therapies. MM is also characterized by a gradual and progressive immune …

… of the immune system in myeloma is becoming increasingly understood. Therapies targeting
the immunological components of myeloma … Furthermore, evidence suggests that immune …

… Multiple myeloma is characterized by progressive immune … imide drug, in the treatment of
multiple myeloma in 1997 and its … started an era of new drug approvals for myeloma including …

… approaches are being evaluated to treat multiple myeloma. An emerging focus has been
to augment autologous anti–multiple myeloma immune responses using both dendritic cell–…

… genes represent yet another therapeutic target in the MM to enhance immune cell activity.
While this review summarizes up-to-date knowledge on emerging mAbs and their therapeutic …

… summary of the Multiple Myeloma microenvironment, and emerging revolutionary therapeutic
… therapy to improve the quality of life for Multiple Myeloma patients. Emerging approaches: …

… in treating multiple myeloma, this disease still remains incurable. Toll-like receptors (TLRs)
are key immune … In multiple myeloma there is a dysregulated signalling of TLRs due to an …